



Preventing and mitigating critical drug shortages



DELIVERING VITAL MEDICATIONS

NEARLY

200M

VIALS OR SYRINGES OF ESSENTIAL GENERICS TO TREAT OVER

90M

PATIENTS

SOLVING CRITICAL DRUG SHORTAGES

80

GENERICS AVAILABLE TO DATE

25

OF CIVICA'S TOP GENERICS INCLUDE 19 ON NATIONAL SHORTAGE, YET CIVICA MEETS ORDER COMMITMENTS

PARTNERING FOR INNOVATION

1,400

HOSPITALS RECEIVING CIVICA MEDICATIONS

BRAND NEW

140K

SQ. FT. MANUFACTURING FACILITY

Critical shortages of essential generic injectable drugs are so commonplace, many U.S. hospitals and health care systems maintain permanent drug response teams just to seek alternatives to unavailable drugs—redirecting time away from direct patient care. Six of the nation's top 10 largest health systems are members of Civica.

Civica Rx was created for the express purpose of preventing and mitigating drug shortages. We ensure that quality generic medications are available and affordable to all. Because eliminating shortages and high prices is in the best interest of patients.

Civica Rx is the nonprofit solution for reliable supplies of quality generic medications. Established by U.S. member hospitals and philanthropic organizations, Civica is ensuring the affordable supply of essential medications used in America's ERs, ICUs and during surgeries. Representing 1,400 hospitals and approximately one-third of all U.S. hospital beds, as of now, Civica has provided nearly

200 million units of medications to help treat over 90 million patients.

Civica is leading a movement for patients, not profits. The drugs we make are identified and prioritized by our member health systems – by doctors and pharmacists on the front lines – as the medications most important for quality patient care.

Civica brings together hospitals and drug manufacturers to work collaboratively, ensuring a reliable supply of drugs for hospitals and predictable volumes for manufacturers.

Civica is also working on direct manufacturing. A state-of-the-art facility based in Virginia will soon produce a steady supply of more

than three dozen sterile injectables, all drugs that are currently in or near shortage status.

The plant will also produce affordable biosimilar insulins, ensuring all Americans have access to lower cost, quality insulins, regardless of their insurance status. Combined, three production lines – one for vials, another for prefilled syringes, and a third to supply prefilled pen cartridges – can produce more than 200 million units annually, which will tremendously impact the availability and cost of these medicines throughout the country.

LEARN MORE at Civicarx.org or contact Michael.Laffin@civicarx.org.